Tag Archives: KERX

Wednesday’s Midday Movers: Rosetta Genomics Ltd (ROSG), ImmunoCellular Therapeutics (IMUC), Curis Inc (CRIS), Keryx Biopharma (KERX), CDTi Advanced Materials Inc (CDTI)

So far Wednesday, December 12, NASDAQ is up 2.2% and the S&P is up 0.74%. Let’s take a look at this morning’s most active stocks and their recent analyst insights; Rosetta Genomics Ltd (ROSG – Research Report), ImmunoCellular Therapeutics (IMUC

Keryx Biopharma (KERX) Receives a Hold from Maxim Group

In a report released today, Jason McCarthy from Maxim Group maintained a Hold rating on Keryx Biopharma (KERX – Research Report). The company’s shares closed yesterday at $3.03, close to its 52-week low of $2.74. McCarthy noted: “Keryx reported 3Q18

Analysts Are Bullish on These Healthcare Stocks: Keryx Biopharma (KERX), Histogenics (HSGX)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Keryx Biopharma (KERX – Research Report), Histogenics (HSGX – Research Report) and Kala Pharmaceuticals Inc (KALA – Research Report) with bullish sentiments.

Keryx Biopharma (KERX) Receives a Buy from H.C. Wainwright

H.C. Wainwright analyst Jason Kolbert maintained a Buy rating on Keryx Biopharma (NASDAQ: KERX) today and set a price target of $9. The company’s shares closed yesterday at $3.32, close to its 52-week low of $2.93. Kolbert commented: “Our therapeutic

Analysts Offer Insights on Healthcare Companies: Keryx Biopharma (NASDAQ: KERX), G1 Therapeutics Inc (NASDAQ: GTHX) and Sarepta Therapeutics (NASDAQ: SRPT)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Keryx Biopharma (NASDAQ:KERX), G1 Therapeutics Inc (NASDAQ:GTHX) and Sarepta Therapeutics (NASDAQ:SRPT) with bullish sentiments. Keryx Biopharma (KERX) H.C. Wainwright analyst Jason Kolbert

Why Did Maxim Group Downgrade Keryx Biopharma’s Stock?

In a report released today, Jason McCarthy from Maxim Group downgraded Keryx Biopharma (NASDAQ: KERX) to Hold. The company’s shares opened today at $4.55. McCarthy wrote: “Therapeutics announced a definitive merger agreement under which the companies will combine in an